| Literature DB >> 34946558 |
Miguel O Suárez-Barrera1,2,3,4, Lydia Visser3, Paola Rondón-Villarreal1, Diego F Herrera-Pineda1, Juan S Alarcón-Aldana1, Anke Van den Berg3, Jahir Orozco4, Efraín H Pinzón-Reyes1, Ernesto Moreno5, Nohora J Rueda-Forero1.
Abstract
Bacillus thuringiensis (Bt) is a bacterium capable of producing Cry toxins, which are recognized for their bio-controlling actions against insects. However, a few Bt strains encode proteins lacking insecticidal activity but showing cytotoxic activity against different cancer cell lines and low or no cytotoxicity toward normal human cells. A subset of Cry anticancer proteins, termed parasporins (PSs), has recently arisen as a potential alternative for cancer treatment. However, the molecular receptors that allow the binding of PSs to cells and their cytotoxic mechanisms of action have not been well established. Nonetheless, their selective cytotoxic activity against different types of cancer cell lines places PSs as a promising alternative treatment modality. In this review, we provide an overview of the classification, structures, mechanisms of action, and insights obtained from genetic modification approaches for PS proteins.Entities:
Keywords: Cry toxins; cancer cells; genetic improvement; parasporins
Mesh:
Substances:
Year: 2021 PMID: 34946558 PMCID: PMC8706377 DOI: 10.3390/molecules26247476
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Parasporin families, family-containing strains, molecular weights, target cells, cytotoxic activity, and references.
| Parasporin | Strain ( | Molecular Mass | Target Cell Line | Cytotoxic Activity | Ref. |
|---|---|---|---|---|---|
| PS1Aa1 | A1190 | 81 | MOLT-4 | 2.2 | [ |
| PS2Aa1 | A1547 | 37 | MOLT-4 | 0.022 | [ |
| PS3Aa1 | A1462 | 93 | MOLT-4 | >10 | [ |
| PS4Aa1 | A1470 | 34 | MOLT-4 | 0.472 | [ |
| PS5Aa1 | A1100 | 31 | MOLT-4 | 0.075 | [ |
| PS6Aa1 | M109/CP84 | 73 | HepG2 | 2.3 | [ |
Figure 1Structural comparison of parasporins. (A) Structural model of higher-molecular-weight PS3Aa1 with its three domains. (B) Low-molecular-weight PS2Aa1 structural model. (C–E) Structural comparison between parasporin-2, the 26-kDa nontoxic protein, and aerolysin-like β-PFT. Membrane-binding-related domain I is colored yellow. The membrane-insertion and pore-formation regions are colored blue (domain II) and red (Domain III). It is suggested that the purple amphipathic β-hairpin is necessary for pore formation (C–E). Parasporin 4 (PS4) was modeled using the 26-kDa nontoxic protein as an adapted template from Xu et al. [9], modified by the authors.
Figure 2Action mode of aerolysin-like parasporins (PS2Aa). Figure adapted from [9]. According to this model, the mechanism of action could be as follows: 1. The solubilized protein binds to the GPI-anchored receptors at the N-terminus. 2. After C-terminal proteolytic digestion, the activated protein monomers assemble (oligomerization). 3. Through reorganization, a transmembrane β-barrel is formed.
Modifications made to Bt toxins to improve their efficacy.
| Type of Modification | Target Insect | Increase or Decrease in Toxicity | Reference | |
|---|---|---|---|---|
| Domain exchanges | ||||
| Domain III Exchange | mCry3Aa |
| The toxicity increased ≥19%. | [ |
| Domain III, II, I Exchange | Cry9Aa |
| The toxicity increased between 4.9 and 5.1 times, concerning parentals. | [ |
| Domain III Exchange | Cry1Ab; Cry1Ac; Cry1Ba; Cry1Ea; Cry1Fa |
| Increased up to 5.5 times for Cry1Fa. | [ |
| Domain III Exchange | Cry1Ca; Cry1Fb; Cry1Ba; Cry1Da; Cry1Ea |
| The toxicity increased 172 and 69.6 times more for Cry1Ca and Cry1Fb, respectively. | [ |
| Domain exchanges of Domains II and III, between Cry1Ia and Cry1Ba. | Cry1Ia; Cry1Ba |
| The toxicity increased up to 1127 and 4.2 times, compared to Cry1Ba and Cry1Ia, correspondingly. | [ |
| Site-directed mutagenesis | ||||
| Loops 1, 2, and 3, domain II substitution. | Cry4Ba |
| The toxicity increased up to 700 times. | [ |
| Loops 1 and 2 domain II substitution | Cry19Aa |
| The toxicity increased up to 42,000 times, concerning the parental. | [ |
| Substitution in the domain II | Cry2Ab |
| The toxicity increased up to 6.75 times. | [ |
| Loops 1 and 2 domain II substitution and deletions. | Cry1Aa |
| Change in insect target. | [ |
| Substitution in the domain III | Cry1Ab |
| The toxicity increased up to 44 times, correspondingly to the parental. | [ |
| Truncated toxins | ||||
| Truncation and selection of mutants, derived from a phage library | Cry1Ia |
| The toxicity increased, showing mortality of 50% for approach. | [ |
| Helix α-1 domain I truncation. | Cry1A |
| The toxicity increased up to 100 and 150 times for Cry1Ab and CryAc, respectively. | [ |
| Helix α-1 domain I truncation. | Cry1A |
| The toxicity increased ≥350 times, against resistant insects. | [ |
| C-terminal truncation | Cry1C |
| The toxicity increased up to 4 times. | [ |
| Phage-display library | ||||
| Selection of mutant toxins from a phage-display library based on their potential of binding. | Cry1Aa |
| Increased the receptor affinity potential up to 16 and 50 times more, contrasting the parentals. | [ |
| Selection of mutant toxins from a phage-display library based on their potential of binding. | Cry8Ka |
| Increased the toxicity up to 3.2 times, contrasting the parental. | [ |
| Selection of mutant toxins from a phage-display library based on their potential of binding in the domain II. | Cry1Aa |
| The toxicity increased between 1.4 and 8.9 times, concerning parentals. | [ |